Scarica l'app Stockscreener
0.8724
0.30%
-0.0012
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MXCT Giù?
Forum
Previsione
Precedente Chiudi:
$0.8736
Aprire:
$0.87
Volume 24 ore:
243.99K
Relative Volume:
0.21
Capitalizzazione di mercato:
$93.33M
Reddito:
$33.03M
Utile/perdita netta:
$-44.63M
Rapporto P/E:
-2.0806
EPS:
-0.4193
Flusso di cassa netto:
$-36.18M
1 W Prestazione:
+0.09%
1M Prestazione:
+27.41%
6M Prestazione:
-43.81%
1 anno Prestazione:
-70.17%
Intervallo 1D:
$0.85
$0.8811
Intervallo di 1 settimana:
$0.8319
$0.8999
Portata 52W:
$0.6434
$2.93
Maxcyte Inc Stock (MXCT) Company Profile
Nome
Maxcyte Inc
Settore
Industria
Telefono
301-517-5556
Indirizzo
9713 KEY WEST AVENUE,, ROCKVILLE
Compare MXCT vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
0.8734 | 93.35M | 33.03M | -44.63M | -36.18M | -0.4193 |
ABT
Abbott Laboratories
|
93.67 | 161.26B | 45.13B | 6.28B | 7.40B | 3.5895 |
SYK
Stryker Corp
|
322.09 | 126.01B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
81.81 | 106.46B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
58.27 | 89.10B | 20.62B | 3.56B | 3.66B | 2.3847 |
EW
Edwards Lifesciences Corp
|
81.98 | 48.12B | 6.30B | 1.07B | 1.34B | 1.8406 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-11 | Downgrade | BTIG Research | Buy → Neutral |
| 2025-08-07 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-07-22 | Iniziato | Stephens | Overweight |
| 2023-11-29 | Iniziato | Craig Hallum | Buy |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-08-24 | Iniziato | BTIG Research | Buy |
| 2021-08-24 | Iniziato | Cowen | Outperform |
| 2021-08-24 | Iniziato | Stephens | Overweight |
| 2021-08-24 | Iniziato | Stifel | Buy |
| 2021-08-24 | Iniziato | Wedbush | Outperform |
| 2021-08-24 | Iniziato | William Blair | Outperform |
Mostra tutto
Maxcyte Inc Borsa (MXCT) Ultime notizie
MaxCyte announces 34% workforce reduction to cut costs - MSN
MaxCyte (MXCT) price target decreased by 14.88% to 4.90 - MSN
MaxCyte sees Q4 core revenue between $6.6M and $6.7M - MSN
MaxCyte, Inc. (MXCT) reports Q4 loss, misses revenue estimates - MSN
MXCT (MaxCyte Inc.) shares fall 4.09 percent despite Q4 2025 EPS beat and double-digit year over year revenue decline.Investment Signal Network - Cổng thông tin điện tử tỉnh Tây Ninh
MXCT (MaxCyte Inc.) shares climb more than four percent after Q4 2025 EPS tops consensus analyst expectations.Risk Report - Cổng thông tin điện tử Tỉnh Sơn La
MaxCyte, Inc. (NASDAQ:MXCT) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Form S-8Securities to be offered to employees in employee benefit plans - ADVFN
Wall Street Zen Downgrades MaxCyte (NASDAQ:MXCT) to Sell - MarketBeat
MaxCyte (MXCT) CFO receives 187,500 restricted stock units in equity grant - Stock Titan
MaxCyte (MXCT) price target decreased by 11.67% to 4.33 - MSN
Earnings Call Summary | MaxCyte(MXCT.US) Q4 2025 Earnings Conference - 富途牛牛
FOMO Trade: Is MaxCyte Inc stock risky to hold nowWeekly Profit Recap & Low Volatility Stock Recommendations - baoquankhu1.vn
Rally Mode: Can MaxCyte Inc sustain its profitability2026 Breakouts & Growth Focused Stock Reports - baoquankhu1.vn
Fed Watch: Will MaxCyte Inc benefit from rising consumer demand2026 Rallies & Weekly Sector Rotation Insights - baoquankhu1.vn
MaxCyte (MXCT) CFO awarded 375,000 employee stock options at $0.6762 - Stock Titan
MAXCYTE (MXCT) CFO Parmeet Ahuja named reporting insider in Form 3 - Stock Titan
Mirabella exit leaves MaxCyte (NASDAQ: MXCT) ownership at 0% after Jan 5, 2026 - Stock Titan
Activity Recap: Is MaxCyte Inc showing insider buying2026 WrapUp & Technical Confirmation Trade Alerts - baoquankhu1.vn
Aug Final Week: Is MaxCyte Inc being accumulated by smart money - baoquankhu1.vn
Aug Rallies: Is MaxCyte Inc a momentum stock2026 Intraday Action & Technical Pattern Alert System - baoquankhu1.vn
Pullback Watch: Is MaxCyte Inc forming a breakout patternWall Street Watch & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
MaxCyte, Inc. (NASDAQ:MXCT) Q4 2025 earnings call transcript - MSN
Quarterly Earnings: Is MaxCyte Inc stock a value trap2026 Key Highlights & Growth Focused Entry Reports - baoquankhu1.vn
Is MaxCyte (MXCT) Stock Good for Passive Investors | Price at $0.74, Down 1.31%Early Entry - UBND thành phố Hải Phòng
MXCT PE Ratio & Valuation, Is MXCT Overvalued - Intellectia AI
MXCT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
MXCT Stock Analysis: MaxCyte Inc. Biotech Play Holds 0.75 Support Post Minor Daily Gain - Cổng thông tin điện tử Tỉnh Sơn La
Big Money Moves: Is MaxCyte Inc stock risky to hold now2026 News Drivers & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
MXCT Stock Analysis: MaxCyte Inc. biotech holds 0.71 dollar mark with mild daily gain - Cổng thông tin điện tử tỉnh Tây Ninh
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
MaxCyte (MXCT) CEO awarded 600,000 options and 300,000 RSUs - Stock Titan
New MaxCyte CFO gets 562,500-share inducement award under Nasdaq rule - Stock Titan
RSI Check: Is now the right time to enter MaxCyte IncTrade Entry Report & Long-Term Growth Portfolio Plans - baoquankhu1.vn
MaxCyte (NASDAQ:MXCT) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Risk On: Will MaxCyte Inc outperform small cap indexes2026 Review & Risk Managed Investment Entry Signals - baoquankhu1.vn
MaxCyte Appoints Parmeet Ahuja as New Chief Financial Officer to Drive Strategic Growth - Minichart
MaxCyte outlines $30M–$32M 2026 revenue target as ExPERT DTx launch and SPL milestones drive outlook - MSN
MaxCyte Earnings Call Weighs Short‑Term Pain, Long‑Term Upside - The Globe and Mail
MaxCyte Appoints New Chief Financial Officer Ahuja - TipRanks
MaxCyte appoints Parmeet Ahuja as CFO, succeeding Douglas Swirsky - TradingView
New MaxCyte (NASDAQ: MXCT) CFO Parmeet Ahuja joins from Agilent - Stock Titan
Vanguard disaggregates holdings; reports 0% stake in MaxCyte (MXCT) - Stock Titan
Maxcyte Inc Azioni (MXCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Maxcyte Inc Azioni (MXCT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Hemrajani Rekha | Director |
Jun 25 '25 |
Sale |
2.09 |
10,684 |
22,378 |
39,893 |
| Swirsky Douglas J | CHIEF FINANCIAL OFFICER |
Aug 13 '25 |
Buy |
1.29 |
50,000 |
64,500 |
161,811 |
| Masoud Maher | President and CEO |
Aug 13 '25 |
Buy |
1.37 |
75,000 |
102,915 |
175,000 |
| Erck Stanley C | Director |
Aug 13 '25 |
Buy |
1.37 |
100,000 |
137,220 |
398,328 |
| DOUGLAS RICHARD | Director |
Aug 13 '25 |
Buy |
1.39 |
80,000 |
111,040 |
230,577 |
| Brooke William W | Director |
Aug 13 '25 |
Buy |
1.29 |
50,000 |
64,500 |
150,879 |
11.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):